Supreme Court Ensures Continued Access to Mifepristone by Mail
WASHINGTON — The Supreme Court confirmed on Thursday that the abortion medication mifepristone will remain available via mail without the requirement of an in-person clinician appointment. This decision effectively safeguards access to the drug amidst ongoing legal challenges.
Impact of the 5th Circuit Court of Appeals Ruling
A ruling on May 1 from the New Orleans-based 5th Circuit Court of Appeals placed significant limits on the access to mifepristone. In response, the Supreme Court granted an emergency request from pharmaceutical companies Danko Laboratories and GenBioPro to suspend the lower court’s judgment while litigation proceeds.
Legal Repercussions in Louisiana
The Supreme Court’s ruling represents a setback for Louisiana, allowing for uninterrupted access to the drug. On May 4, Justice Samuel Alito issued an order to put the appeals court’s ruling on hold temporarily as the justices contemplate their next course of action.
Dissenting Opinions Among Justices
Two conservative justices, Clarence Thomas and Samuel Alito, expressed dissent. Thomas criticized the pharmaceutical companies, asserting that the act of mailing mifepristone is illegal in Louisiana and admonished their opposition to the court order, claiming it stems from “lost profits from a criminal enterprise.”
Concerns Over Abortion Rights
In his dissent, Alito characterized the Biden administration’s action to facilitate mail access to mifepristone as an effort to “undermine” a 2022 ruling that reversed the landmark Roe v. Wade decision. He stated, “Louisiana’s efforts are being thwarted by certain health care providers and states that wish to undermine enforcement of laws like Louisiana’s.”
Responses from Advocacy Groups
The decision was met with approval from abortion rights advocates. Alexis McGill Johnson, president of the Planned Parenthood Action Fund, commented that while the Supreme Court’s ruling was minimal, it provides relief for patients who rely on the drug. She acknowledged the ongoing attacks on reproductive rights, highlighting the importance of continued access to care.
Background on Mifepristone and Ongoing Legal Issues
The underlying case involves Louisiana’s challenge to the FDA’s decision during the Biden administration, which allows mifepristone to be prescribed without an in-person consultation even in states with restrictive abortion laws. Despite research indicating its safety and efficacy, anti-abortion groups are advocating for reinstating the in-person dispensing requirement, deeming home use dangerous.
Implications for the Future of Mifepristone
While Louisiana Attorney General Liz Murrill opposes the Supreme Court’s intervention, claiming that mail-based access has resulted in significant abortion numbers monthly despite the state’s near-total ban, she expressed her disappointment with the ruling’s implications for medical ethics. As the FDA continues to review safety protocols surrounding mifepristone, its accessibility by mail remains at risk, with ongoing legal battles that could alter its status.
